Perceptions and Practices of Primary Care Providers in Europe and the US in the Diagnosis and Treatment of Irritable Bowel Syndrome: A Multinational Survey
- PMID: 39568286
- PMCID: PMC11748826
- DOI: 10.1111/nmo.14967
Perceptions and Practices of Primary Care Providers in Europe and the US in the Diagnosis and Treatment of Irritable Bowel Syndrome: A Multinational Survey
Abstract
Background: The knowledge and proficiency of primary care practitioners (PCPs) in diagnosing and managing irritable bowel syndrome (IBS) remain generally low and variable internationally. This variability is partly due to a lack of familiarity with the Rome Foundation diagnostic criteria and treatment guidelines for this condition.
Methods: We conducted an electronic survey of PCPs in the United States and nine European countries to assess their understanding of IBS pathophysiology; the use of Rome IV criteria in diagnosis, knowledge of and frequency in prescribing various recommended treatments; and the likelihood of referring patients with suspected IBS to subspecialists.
Results: Most PCPs in the United States and Europe perceive IBS as a diagnosis of exclusion rather than a definitive diagnosis. They also believe IBS is underdiagnosed in primary care and challenging to diagnose confidently. The majority of PCPs consider diet as a crucial component of IBS management. Notably, US PCPs reported greater confidence than their European counterparts in recommending dietary interventions such as increased dietary fiber, a low FODMAP diet, and gluten restriction. Conversely, both groups exhibited moderate to high confidence in recommending over-the-counter treatments. European PCPs showed greater confidence in treating IBS with antispasmodics and secretagogues, while US PCPs expressed greater confidence in prescribing neuromodulators. Additionally, US PCPs were more likely to refer patients with suspected IBS to a gastroenterologist, whereas both US and European PCPs showed similar referral patterns to dietitians and referred very few patients to mental health providers. Both US and European PCPs reported that IBS is moderately to extremely difficult to treat effectively and emphasized the importance of a strong and longitudinal doctor-patient relationship in managing the condition.
Conclusion: Despite the Rome Foundation recommendations and criteria to support a positive diagnosis of IBS, most PCPs still rely on exclusionary investigations such as endoscopy and a serologic workup, while a significant percentage suggest referring patients to gastroenterologists.
Keywords: diagnosis; disorders of gut‐brain interaction (DGBI); epidemiology; functional gastrointestinal disorders (FGID); irritable bowel syndrome (IBS); primary care; treatment.
© 2024 The Author(s). Neurogastroenterology & Motility published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
Diagnosing and managing irritable bowel syndrome with predominant diarrhoea in clinical practice: online survey among gastroenterologists and general practitioners.Acta Gastroenterol Belg. 2024 Apr-Jun;87(2):229-234. doi: 10.51821/87.2.12586. Acta Gastroenterol Belg. 2024. PMID: 39210754
-
Diagnosis of Irritable Bowel Syndrome: Primary Care Physicians Compared with Gastroenterologists.Clin Med Res. 2023 Sep;21(3):129-135. doi: 10.3121/cmr.2023.1817. Clin Med Res. 2023. PMID: 37985167 Free PMC article.
-
Use of Rome criteria for the diagnosis of irritable bowel syndrome in primary care: a survey among European countries.Eur J Gastroenterol Hepatol. 2017 Jun;29(6):651-656. doi: 10.1097/MEG.0000000000000848. Eur J Gastroenterol Hepatol. 2017. PMID: 28125426
-
Irritable bowel syndrome - controversies in diagnosis and management.Expert Rev Gastroenterol Hepatol. 2023 Jul-Dec;17(7):649-663. doi: 10.1080/17474124.2023.2223975. Epub 2023 Jun 20. Expert Rev Gastroenterol Hepatol. 2023. PMID: 37317843 Review.
-
Doctor-patient interaction for irritable bowel syndrome in primary care: a systematic perspective.Eur J Gastroenterol Hepatol. 2004 Nov;16(11):1161-6. doi: 10.1097/00042737-200411000-00013. Eur J Gastroenterol Hepatol. 2004. PMID: 15489576 Review.
References
-
- Sperber A. D., Bangdiwala S. I., Drossman D. A., et al., “Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study,” Gastroenterology 160, no. 1 (2021): 99–114.e3. - PubMed
-
- Palsson O. S., Whitehead W., Törnblom H., Sperber A., and Simren M., “Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada and United Kingdom,” Gastroenterology 158 (2020): 1262–1273. - PubMed
-
- Aziz I., Palsson O. S., Törnblom H., Sperber A. D., Whitehead W. E., and Simrén M., “The Prevalence and Impact of Overlapping Rome IV‐Diagnosed Functional Gastrointestinal Disorders on Somatization, Quality of Life, and Healthcare Utilization: A Cross‐Sectional General Population Study in Three Countries,” American Journal of Gastroenterology 113, no. 1 (2018): 86–96. - PubMed
-
- Chang L., Sultan S., Lembo A., Verne G. N., Smalley W., and Heidelbaugh J. J., “AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation,” Gastroenterology 163, no. 1 (2022): 118–136. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources